Australia's largest stock trading and investment forum Australia's #1 stock forum

NUH

0.00%

8.1¢ nuheara limited

Ann: Results of Meeting, page-64

First 64 Last

Share
Profile

Follow
pastperformer

7,391 Posts.

2231

08/07/24

16:43

Post #: 74658295
Share

Originally posted by the trickster: ↑

I am sorry but your argument is false.

You cannot suggest that based on the 4D balance date 31st Dec 2023 they are trading insolvent when they had more cash on hand as a result of the capital raise in November as well as the R&D tax rebate than the prior half yr.

If you are going to argue that they are insolvent as at 31st Dec 2023, then they are insolvent as at 30th June 2023.

Not lodging the 4D doesnt give you any protection from trading while insolvent rules and the penalties are severe including potential jail time.

I told you the reason why they are in a trading halt, they are using the 4D as a mechanism to trigger an extended trading halt while they engage in negotiations. You don’t seem to be paying attention.
Its a very unethical and corrupt mechanism to use but technically not illegal. They can hold it back based on directors not signing off or argument over some technicality. The fact that they have lodged the latest 4C and the fact that accounts can be reconstructed forensically, they have no where to hide if they are deliberately trading while insolvent, and that does not mean just trading on the exchange, it means trading in “business”. Not lodging a 4D is no protection from the law. Your argument that they havent lodged the prior 4D because of insolvent trading is nonsensical.

Unfortunately the CEOof NUH and the Board are not morally upstanding corporate citizens but behave as shysters.

As soon as the 4D is lodged, they have limited levers available to stop the ASX re-instating them for trade. Miller’s behaviour is unconscionable. And to think this quack believes he is entitled to performance shares. It will be interesting how this works with respect to insider trading rules. Allocating yourself shares while negotiating deals is no different to buying on market based on insider information. We shall see what will happen in time but certainly it may present as a serious problem depending on how events transpire.

My monthly cash burn estimate is reasonable , typically they average around $1.8mln plus per qtr sometimes allot more, but they have cut that way down , cutting salary expenses, marketing expenses etc. We dont know the exact details are as the accounts have not been released for the last qtr but $500k/month seems to be a reasonable estimate to work with. It may be a little higher or lower, but it is certainly not way off the way you are suggesting.

Expand

I love reading your posts, it reminds me of what makes a market. In most cases there is always somebody so convinced of their own narrative they are willing to put a lot of money on the line.

Never change.

NUH Price at posting: 8.1¢ Sentiment: Sell Disclosure: Not Held
4 Upvote

2 Great analysis

Reply

Top Stories

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

There are more pages in this discussion • 13 more messages in this thread...

First 64 Last

Add NUH (ASX) to my watchlist

(20min delay)
Last 8.1¢		Change 0.000(0.00%)		Mkt cap ! $21.75M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Ann: Results of Meeting, page-64

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Featured News

Ann: Results of Meeting, page-64

Top Stories

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Featured News